• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

BLAZE-1 RCT Results: Bamlanivimab and Etesevimab Monoclonal Antibody Treatments

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Bamlanivimab and etesevimab are both antispike neutralizing monoclonal antibody treatments granted emergency use authorization as treatments for COVID-19
  • Gottlieb et al. (JAMA, 2021) examined the effect of bamlanivimab, and combination therapy with bamlanivimab and etesevimab in patients with mild to moderate COVID-19

METHODS:

  • Randomized phase 2/3 trial
    • BLAZE-1 (Blocking Viral Attachment and Cell Entry with SARS-CoV-2 Neutralizing Antibodies) Trial
  • Setting
    • 49 US centers
  • Participants
    • Ambulatory patients who tested positive for SARS-CoV-2 and had one or more mild to moderate symptoms
  • Interventions
    • Bamlanivimab therapy only
      • Single infusion of either
        • 700 mg
        • 2800 mg
        • 7000 mg
    • Combination therapy
      • 2800 mg of bamlanivimab and 2800 mg of etesevimab
    • Placebo
  • Primary outcomes
    • Change in SARS-CoV-2 log viral load at day 11 (±4 days)
  • Secondary outcomes
    • Other measures of viral load
    • Symptoms
    • Clinical outcomes: Hospitalization, emergency department visit, or death)

RESULTS:

  • 533 patients completed evaluation
    • Mean (SD) age: 44.7 (15.7) years
    • 54.6% women
    • Bamlanivimab group: 309 participants (distributed evenly between dosing strengths)
    • Combination group: 112 participants
    • Placebo: 156 participants
  • Change in log viral load from baseline to day 11
    • 700 mg bamlanivimab: –3.72
    • 2800 mg bamlanivimab: –4.08
    • 7000 mg bamlanivimab: –3.49
    • Combination: –4.37
    • Placebo: –3.80
  • Differences in change in log viral load at day 11, compared to placebo
    • 700 mg bamlanivimab: 0.09 (95%,  CI –0.35 to 0.52; P = 0.69)
    • 2800 mg bamlanivimab: –0.27 (95% CI, –0.71 to 0.16; P = 0.21)
    • 7000 mg bamlanivimab: 0.31 (95% CI, –0.13 to 0.760; P = 0.16)
    • Combination: –0.57 (95% CI, –1.00 to –0.14; P = 0.01)
  • Proportion of patients with COVID-19-related hospitalizations or ED visits
    • 700 mg bamlanivimab: 1.0% (1 event)
    • 2800 mg bamlanivimab: 1.9% (2 events)
    • 7000 mg bamlanivimab: 2.0% (2 events)
    • Combination: 0.9% (1 event)
    • Placebo: 5.8% (9 events)
  • Immediate hypersensitivity reactions were reported in some patients
    • Bamlanivimab: 6 patients
    • Combination: 2 patients
    • Placebo: 1 patient
  • No deaths occurred during the study

CONCLUSION:

  • For patients with mild to moderate COVID-19, treatment with combined bamlanivimab and etesevimab monoclonal antibodies led to reduction in viral load at day 11, compared to placebo
    • With bamlanivimab therapy only there was no significant reduction in viral load
  • An editorial points out that viral load (primary endpoint) can change over the disease course | Hospitalizations (a secondary outcome) may be a more clinically relevant outcome

While the world waits for widespread administration of effective vaccines and additional data on treatments, local efforts should work to improve testing access and turnaround time and reduce logistical barriers to ensure that monoclonal therapies can be provided to patients who are most likely to benefit 

Learn More – Primary Sources:

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

JAMA Editorial: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

ACTT-1 Remdesivir RCT: Preliminary Results Now Published
COVID-19 Treatment RCT Results: Combination Interferon beta-1b, Lopinavir-Ritonavir and Ribavirin
Does Convalescent Plasma Therapy Reduce Time to Clinical Improvement in Patients with COVID-19?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site